Virtu Financial LLC Acquires 4,611 Shares of Royalty Pharma plc (NASDAQ:RPRX)

Virtu Financial LLC lifted its holdings in shares of Royalty Pharma plc (NASDAQ:RPRX) by 49.7% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 13,888 shares of the biopharmaceutical company’s stock after acquiring an additional 4,611 shares during the quarter. Virtu Financial LLC’s holdings in Royalty Pharma were worth $390,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the business. NEOS Investment Management LLC increased its holdings in shares of Royalty Pharma by 5.0% in the fourth quarter. NEOS Investment Management LLC now owns 8,589 shares of the biopharmaceutical company’s stock valued at $241,000 after purchasing an additional 409 shares during the last quarter. Beck Bode LLC raised its holdings in Royalty Pharma by 0.6% in the 4th quarter. Beck Bode LLC now owns 73,042 shares of the biopharmaceutical company’s stock valued at $2,052,000 after acquiring an additional 464 shares during the period. Toroso Investments LLC lifted its position in Royalty Pharma by 0.9% during the third quarter. Toroso Investments LLC now owns 57,102 shares of the biopharmaceutical company’s stock worth $1,550,000 after acquiring an additional 504 shares during the last quarter. PNC Financial Services Group Inc. boosted its holdings in shares of Royalty Pharma by 10.8% during the third quarter. PNC Financial Services Group Inc. now owns 5,509 shares of the biopharmaceutical company’s stock worth $150,000 after acquiring an additional 536 shares during the period. Finally, Treasurer of the State of North Carolina boosted its holdings in shares of Royalty Pharma by 0.4% during the third quarter. Treasurer of the State of North Carolina now owns 173,196 shares of the biopharmaceutical company’s stock worth $4,701,000 after acquiring an additional 642 shares during the period. 54.35% of the stock is owned by institutional investors and hedge funds.

Royalty Pharma Price Performance

Shares of NASDAQ:RPRX opened at $26.26 on Wednesday. The firm has a 50 day moving average of $27.62 and a 200-day moving average of $28.61. Royalty Pharma plc has a 12 month low of $25.92 and a 12 month high of $31.93. The company has a current ratio of 12.52, a quick ratio of 12.52 and a debt-to-equity ratio of 0.62. The stock has a market capitalization of $15.69 billion, a PE ratio of 19.60, a PEG ratio of 3.51 and a beta of 0.47.

Royalty Pharma (NASDAQ:RPRX) last announced its quarterly earnings data on Thursday, May 9th. The biopharmaceutical company reported $0.98 EPS for the quarter, beating the consensus estimate of $0.96 by $0.02. The business had revenue of $568.00 million during the quarter, compared to the consensus estimate of $671.45 million. Royalty Pharma had a net margin of 35.70% and a return on equity of 22.94%. During the same period in the previous year, the business earned $1.60 earnings per share. On average, equities research analysts predict that Royalty Pharma plc will post 4.03 EPS for the current fiscal year.

Royalty Pharma Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, June 14th. Investors of record on Friday, May 17th were paid a $0.21 dividend. This represents a $0.84 annualized dividend and a yield of 3.20%. The ex-dividend date was Thursday, May 16th. Royalty Pharma’s dividend payout ratio (DPR) is presently 62.69%.

Analyst Ratings Changes

RPRX has been the subject of several research reports. JPMorgan Chase & Co. dropped their price target on Royalty Pharma from $45.00 to $42.00 and set an “overweight” rating for the company in a report on Tuesday, February 20th. Bank of America decreased their price target on shares of Royalty Pharma from $40.00 to $38.00 and set a “buy” rating on the stock in a research note on Friday, April 12th. StockNews.com cut shares of Royalty Pharma from a “buy” rating to a “hold” rating in a research note on Friday, May 10th. UBS Group lowered shares of Royalty Pharma from a “buy” rating to a “neutral” rating and set a $28.00 target price on the stock. in a research report on Monday, June 3rd. Finally, The Goldman Sachs Group dropped their price target on shares of Royalty Pharma from $56.00 to $50.00 and set a “buy” rating for the company in a research report on Tuesday, February 20th. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, Royalty Pharma presently has an average rating of “Moderate Buy” and a consensus price target of $43.00.

Royalty Pharma Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.